Dr.Yi You
Associate Professor, Institute of Cardiovascular Diseases, Soochow University
Outstanding Young Scholar of Soochow University
Member of the Chinese Association of Pathophysiology
E-mail: youyi@suda.edu.cn
Biography
Yi You received his Ph.D. in Chemical Genomics from Peking University. His research focuses on engineered extracellular vesicles (exosomes), targeted delivery of nucleic acid therapeutics, construction and application of cardiac organoids, and gene and cell therapies for rare diseases. His research achievements have been published as first or co-first author in leading international journals, including Nature Biomedical Engineering, European Heart Journal, and Journal of Extracellular Vesicles, with a total of nine SCI-indexed publications. He developed the first-in-class nucleic acid therapeutic based on an extracellular vesicle delivery platform (SPOT-001 Injection), which has received approval for Investigator-Initiated Trial (IIT) clinical application and attracted over USD 30 million in Series A financing from institutions including IDG Capital and Shangcheng Capital. He currently serves as the Principal Investigator of several research projects, including the Young Scientists Fund of the National Natural Science Foundation of China, the National Stem Cell Program of China, and the Young Talent Support Program of the Suzhou Association for Science and Technology. He has filed and been granted two Chinese invention patents and one international patent, and serves as a Young Editorial Board Member of Organoid Research.
Publications：Research Articles (# Co-first author, * Co-corresponding author)
1. You Y#, Tian Y#, Guo R, Shi J, Kwak KJ, Tong Y, Estania AP, Hsu WH, Liu Y, Hu S, Cao J, Yang L, Bai R, Huang P, Lee LJ, Jiang W, Kim BYS, Ma S, Liu X, Shen Z*, Lan F*, Phuong Nguyen PK*, Lee AS*. Extracellular vesicle-mediated VEGF-A mRNA delivery rescues ischaemic injury with low immunogenicity. Eur Heart J. 2025 May 2;46(17):1662-1676.
2. You Y#, Tian Y#, Yang Z#, Shi J, Kwak KJ, Tong Y, Estania AP, Cao J, Hsu WH, Liu Y, Chiang CL, Schrank BR, Huntoon K, Lee D, Li Z, Zhao Y, Zhang H, Gallup TD, Ha J, Dong S, Li X, Wang Y, Lu WJ, Bahrani E, Lee LJ, Teng L, Jiang W, Lan F*, Kim BYS*, Lee AS*. Intradermally delivered mRNA-encapsulating extracellular vesicles for collagen-replacement therapy. Nat Biomed Eng. 2023 Jul;7(7):887-900.
3. Yan Y, You Y#, Ma S, Yi H, Chen G, Ni J, Chen C, Ke W, Li L, Bai R, Ran Y, Lu W, Zhu M, Zhang Y, Dai J, Qi M, Lan F, Lee AS, Zhang R, Liu X, Chen Z. Efficient Scaling up EV-AAVs Production via Cellular Nanoporation for Familial Hypercholesterolaemia Therapy. J Extracell Vesicles. 2025 Nov;14(11):e70186. doi: 10.1002/jev2.70186. PMID: 41216903; PMCID: PMC12603781.
4. Bai R, Zhang S, Gu X, You Y*, Liu X*. Establishment of a TRPV2 knockout human embryonic stem cell line (WAe009-A-1Y) using episomal vector-based CRISPR/Cas9. Stem Cell Res. 2025 Sep; 87:103744. doi: 10.1016/j.scr.2025.103744. Epub 2025 May 30. PMID: 40483902.
5. Cao Y#, You Y#, Wang Q#, Ren X, Li S, Li L, Xia W, Guan X, Yang T, Ikegawa S, Wang Z, Zhao X*. Identification of six novel variants from nine Chinese families with hypophosphatemic rickets. BMC Med Genomics. 2022 Jul 16;15(1):161.
6. Li S#, You Y#, Gao J, Mao B, Cao Y, Zhao X*, Zhang X*. Novel mutations in TPM2 and PIEZO2 are responsible for distal arthrogryposis (DA) 2B and mild DA in two Chinese families. BMC Med Genet. 2018 Oct 3;19(1):179. BMC medical genetics, 2018, 19: 1-11.
7. You Y#, Wang X#, Li S, Zhao X*, Zhang X*. Exome sequencing reveals a novel MFN2 missense mutation in a Chinese family with Charcot-Marie-Tooth type 2A. Exp Ther Med. 2018 Sep;16(3):2281-2286.
8. Mao B#, Zhang J#, You Y#, Xiao J, Zhao X*. Mutations in the highly conserved 1A rod domain of keratin 9 responsible for epidermolytic palmoplantar keratoderma in four Chinese families. J Dermatol. 2018 Feb;45(2):e45-e46.
9. Ma Z#, Li M#, Guo R#, Tian Y#, Zheng Y, Huang B, You Y, Xu Q, Cui M, Shen L, Lan F, Yang H, Liu R, Yang T, Wan F, He Q, Huo X, Bi Y, Zhang Y*, Ling Y*. Treating myocardial infarction via a nano-ultrasonic contrast agent-mediated high-efficiency drug delivery system targeting macrophages. Sci Adv. 2025 Jan 3;11(1):eadp7126.
